INBRAIN Neuroelectronics, a Barcelona, Spain-based brain-computer interface therapeutics (BCI-Tx) company, raised $50M in Series B funding.
The round, which brought the total amount to $68M, was led by imec.xpand with new investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa. Existing investors Asabys Partners, Aliath Bioventures and Vsquared also participated.
The company intends to use the funds to advance clinical trials for BCI therapeutics and support the team expansion to accelerate development and commercialization.
Led by CEO Carolina Aguilar, INBRAIN Neuroelectronics is providing real-time precision neurology with a graphene-based brain-computer interface therapeutics (BCI-Tx) platform. Its technology combines advanced neural decoding and micrometric modulation to deliver personalized, adaptive treatments for conditions like Parkinson’s, epilepsy, and stroke rehabilitation.
INBRAIN recently achieved a major milestone with the human application of its graphene-based BCI in an ongoing clinical trial at Salford Royal Hospital in Manchester, UK. The trial aims to evaluate the safety of INBRAIN’s device in patients with brain cancer and will enroll up to ten participants to assess the superiority of graphene over traditional materials for neural applications.
As part of the funding round, INBRAIN is also announcing a collaboration agreement with imec, an independent nanoelectronics hub which will support the company in preparing to scale graphene interfaces at a commercial level.
In addition to the Series B round, INBRAIN also secured additional funding and support from Merck KGaA to advance the clinical development of its technology in Merck’s therapeutic areas of interest. This partnership will boost the translation of INBRAIN’s platform to human use, expanding its impact across both central and peripheral nervous system applications.
FinSMEs
29/10/2024